BioRestorative Therapies
40 Marcus Drive
Suite one
Melville, Long Island
New York
11747
United States
Tel: 6317608405
Website: http://www.biorestorative.com/
Email: hr@BIORESTORATIVE.COM
149 articles about BioRestorative Therapies
-
BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program
3/10/2022
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson, Professor of the Department of Molec
-
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
2/16/2022
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s BRTX-100® core clinical program.
-
BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway
2/7/2022
BioRestorative Provides Update on its Active Phase 2 Clinical Trial.
-
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
2/2/2022
BioRestorative Therapies, Inc. today announced that the Japanese Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem ® Program.
-
BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Magazine
1/26/2022
BioRestorative Therapies, Inc. today announced that it has been named by Insights Care Magazine as one of the ten most innovative regenerative medicine companies in 2022 for its work in developing novel cell-based therapeutics.
-
BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance
1/11/2022
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance.
-
BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference
1/6/2022
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that Lance Alstodt, its Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually from January 10-13, 2022.
-
BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells
1/4/2022
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has been awarded a Small Business Technology Transfer Phase I grant for $256,000.
-
BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
12/21/2021
BioRestorative Therapies, Inc. today announced its Chief Executive Officer, Lance Alstodt, will be featured on the James Hicks “NewMedia Show” on Tuesday, December 21st.
-
BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
12/21/2021
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced it has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO) specializing in clinical trial management to conduct BioRestorative’s Phase 2 clinical trial.
-
BioRestorative Therapies, Inc. Releases Year-End Message
12/20/2021
BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, released the following year-end message.
-
BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program
12/2/2021
BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced that it has filed ten patent applications related to its BRTX-100 program for treating chronic lumbar disc disease with the United States Patent and Trademark Office.
-
BioRestorative Therapies Enters into Letter of Intent with PRC Clinical
11/19/2021
BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced that it has entered into a letter of intent with PRC Clinical, a CRO specializing in clinical trial management, with regard to PRC Clinical providing startup clinical project management activities for the Company’s BRTX-100 Phase 2 clinical trial to treat chronic lumbar disc disease.
-
BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer
11/10/2021
BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced that it has appointed Robert Kristal to the position of Chief Financial Officer.
-
BioRestorative Therapies Announces Closing of $23 Million Public Offering
11/9/2021
BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced the closing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00.
-
BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market
11/5/2021
BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced the pricing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00.
-
BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors
10/26/2021
BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced the nomination of two new independent members to its Board of Directors with industry and medical device experience: Patrick F. Williams, Chief Financial Officer at STAAR Surgical, and David Rosa, President and Chief Executive Officer at NeuroOne.
-
BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
10/26/2021
BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced its intention to effect a 1-for-4,000 reverse split of its common stock in preparation for the planned listing of the Company’s securities on The Nasdaq Capital Market.
-
BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program
9/23/2021
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance for a patent application for its metabolic ThermoStem® program.
-
BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program
9/2/2021
BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Australian Patent Office has issued the Company a patent related to its metabolic ThermoStem® Program.